Cover Image

Heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination induces strong humoral responses among health care workers

Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups. In this prospective, single-center study we included 166 health care workers from Heidelberg University Hosp...

Full description

Saved in:
Bibliographic Details
Main Authors: Benning, Louise (Author) , Töllner, Maximilian (Author) , Hidmark, Asa S. (Author) , Schaier, Matthias (Author) , Nußhag, Christian (Author) , Kälble, Florian (Author) , Reichel, Paula (Author) , Buylaert, Mirabel (Author) , Grenz, Julia (Author) , Ponath, Gerald (Author) , Klein, Katrin (Author) , Zeier, Martin (Author) , Süsal, Caner (Author) , Schnitzler, Paul (Author) , Morath, Christian (Author) , Speer, Claudius (Author)
Format: Article (Journal)
Language:English
Published: 4 August 2021
In: Vaccines
Year: 2021, Volume: 9, Issue: 8, Pages: 1-13
ISSN:2076-393X
DOI:10.3390/vaccines9080857
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/vaccines9080857
Verlag, lizenzpflichtig, Volltext: https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=DOISource&SrcApp=WOS&KeyAID=10.3390%2Fvaccines9080857&DestApp=DOI&SrcAppSID=C4n4cw28dt22OQLhE6J&SrcJTitle=VACCINES&DestDOIRegistrantName=MDPI+AG
Get full text
Author Notes:Louise Benning, Maximilian Töllner, Asa Hidmark, Matthias Schaier, Christian Nusshag, Florian Kälble, Paula Reichel, Mirabel Buylaert, Julia Grenz, Gerald Ponath, Katrin Klein, Martin Zeier, Caner Süsal, Paul Schnitzler, Christian Morath and Claudius Speer
Description
Summary:Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups. In this prospective, single-center study we included 166 health care workers from Heidelberg University Hospital who received either heterologous ChAdOx1 nCoV-19/BNT162b2, homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination between December 2020 and May 2021. We measured anti-S1 IgG, SARS-CoV-2 specific neutralizing antibodies, and antibodies against different SARS-CoV-2 fragments 0-3 days before and 19-21 days after boost vaccination. Before boost, 55/70 (79%) ChAdOx1 nCoV-19-primed compared with 44/45 (98%) BNT162b2-primed individuals showed positive anti-S1 IgG with a median (IQR) anti-S1 IgG index of 1.95 (1.05-2.99) compared to 9.38 (6.26-17.12). SARS-CoV-2 neutralizing antibodies exceeded the threshold in 24/70 (34%) of ChAdOx1 nCoV-19-primed and 43/45 (96%) of BNT162b2-primed individuals. After boosting dose, median (IQR) anti-S1 IgG index in heterologous ChAdOx1 nCoV-19/BNT162b2 vaccinees was 116.2 (61.84-170), compared to 13.09 (7.03-29.02) in homologous ChAdOx1 nCoV-19 and 145.5 (100-291.1) in homologous BNT162b2 vaccinees. All boosted vaccinees exceeded the threshold for neutralization, irrespective of their vaccination scheme. Vaccination was well-tolerated overall. We show that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.
Item Description:Gesehen am 06.10.2021
Physical Description:Online Resource
ISSN:2076-393X
DOI:10.3390/vaccines9080857

Similar Items